Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Open access
Wilson, Jonathan M., Nikooienejad, Amir, Robins, Deborah A., Roell, William C., Riesmeyer, Jeffrey S., Haupt, Axel, Duffin, Kevin L., Taskinen, Marja‐Riitta, Ruotolo, Giacomo · 2020 · Diabetes, Obesity and Metabolism

Abstract

Aim: To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein‐related biomarkers were measured post hoc in available samples from the same study. Materials and Methods: Patients were randomized to receive once‐weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo. Serum lipoprotein profile, apolipoprotein (apo) A‐I, B and C‐III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks. Lipoprotein particle profile by nuclear magnetic resonance was assessed at baseline and 26 weeks. The lipoprotein insulin resistance (LPIR) score was calculated. Results: At 26 weeks, tirzepatide dose‐dependently decreased apoB and apoC‐III levels, and increased serum preheparin LPL compared with placebo. Tirzepatide 10 and 15 mg decreased large triglyceride‐rich lipoprotein particles (TRLP), small low‐density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide. Treatment with dulaglutide also reduced apoB and apoC‐III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score. The number of total LDLP was also decreased with tirzepatide 10 and 15 mg compared with placebo. A greater reduction in apoC‐III with tirzepatide was observed in patients with high compared with normal baseline triglycerides. At 26 weeks, change in apoC‐III, but not body weight, was the best predictor of changes in triglycerides with tirzepatide, explaining up to 22.9% of their variability. Conclusions: Tirzepatide treatment dose‐dependently decreased levels of apoC‐III and apoB and the number of large TRLP and small LDLP, suggesting a net improvement in atherogenic lipoprotein profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14174

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 27

  1. 10.2337/diacare.27.6.1496 · DOI · Paper page
  2. 10.1007/s11886-002-0113-6 · DOI
  3. 10.1016/j.amjcard.2016.02.011 · DOI · Paper page
  4. 10.1007/s11883-016-0614-1 · DOI
  5. 10.1007/s11883-019-0791-9 · DOI
  6. 10.1097/MOL.0000000000000502 · DOI
  7. 10.1172/JCI111711 · DOI · Paper page
  8. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  9. 10.1007/s00125-009-1611-5 · DOI · Paper page
  10. 10.1016/j.numecd.2014.06.010 · DOI
  11. 10.2174/187152512803530315 · DOI
  12. 10.3390/ijms20174092 · DOI · Paper page
  13. 10.1194/jlr.M006841 · DOI · Paper page
  14. 10.1016/j.jacl.2018.11.009 · DOI
  15. 10.2307/1924766 · DOI · Paper page
  16. 10.1111/j.1463-1326.2011.01555.x · DOI
  17. 10.1093/ajcn/71.1.13 · DOI
  18. 10.1016/j.atherosclerosis.2016.08.014 · DOI
  19. 10.2337/db19-980-P · DOI
  20. 10.1055/s-0033-1358527 · DOI
  21. 10.1016/j.cmet.2017.11.003 · DOI
  22. 10.1016/j.jacl.2017.02.012 · DOI
  23. 10.1016/S0022-2275(20)39938-7 · DOI · Paper page
  24. 10.1172/JCI200419992 · DOI
  25. 10.1161/ATVBAHA.110.220723 · DOI · Paper page
  26. Kamagate A, 2008, FoxO1 mediates insulin‐dependent regulation of hepatic VLDL production in mice, J Clin Invest., 118, 2347
  27. 10.1007/s00125-005-1753-z · DOI

Cited by

See all 164

Metadata

Authors
Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-09-15
Volume
22
Issue
12
Pages
2451-2459
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3049084794
Cited by
164
References
21
FWCI
12.42
Type
journal article
Language
en
Open access
hybrid
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.14174
The paper
Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020). The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.